Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Jundishapur Journal of MicrobiologyOpen Access

Evaluation of the Activity of Amoxicillin/Clavulanate, Ceftazidime/Avibactam and Colistin Against Drug-Resistant Mycobacterium tuberculosis Isolates by the E-test Method

View Full Paper
Ask AI
Bookmark
Share

Authors

CACemilenur AtaşTATuba AstarciogluKYKübra Yıldırım

Discussion

Loading...

Member takes

Overview

Study evaluates anti-TB activity of CAV and AMO/CLAV in drug-resistant mycobacterium tuberculosis isolates, indicating potential improvements in treatment.

Key Points

  • Ceftazidime/avibactam was more effective than amoxicillin/clavulanate in treating drug-resistant strains.
  • Minimum inhibitory concentrations for ceftazidime/avibactam were between 0.016 - 0.023 µg/mL for about 65.71% of isolates.
  • Amoxicillin/clavulanate showed varying efficacy with some isolates resistant at > 256 µg/mL.
  • Colistin displayed mixed results, with some isolates showing effectiveness at 0.047 - 0.5 µg/mL while others were resistant beyond 256 µg/mL.

Cite This Study

Ataş et al. (2025) studied this question.

synapsesocial.com/papers/68c23fc3b210217d64798500https://doi.org/10.5812/jjm-162034
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dilution susceptibility testing method evaluation for the combination of ceftibuten and avibactam against Enterobacterales2025
  2. 2Global susceptibility profiles and potential resistance mechanisms of ceftazidime–avibactam-resistant, non-carbapenemase-producing carbapenem-resistant Enterobacterales: 2020–23 data from the Antimicrobial Testing Leadership and Surveillance2025
  3. 3A Tentative Clinical Study: Colistin Combined with Ceftazidime/Avibactam in the Treatment of Carbapenem-Resistant Gram-Negative Bacilli Infection2025
  4. 4In Vitro Activity of Cefiderocol and Aztreonam/Avibactam Against Gram-Negative Non-Fermenting Bacteria: A New Strategy Against Highly Antibiotic-Resistant Infectious Agents2025 · 4 citations
  5. 5IN VITRO SUSCEPTIBILITY COMPARISON OF AZTREONAM ALONG WITH CEFTAZIDIME-AVIBACTAM SYNERGY TESTING METHODS AND AZTREONAMAVIBACTAM AGAINST CARBAPENEM RESISTANT ORGANISMS IN ISOLATES OBTAINED FROM CANCER PATIENTS2025